Mayo Clinic: Alzheimer Disease trials

The registry lists 23 Alzheimer Disease studies with Mayo Clinic as lead sponsor. 8 are open to participants now and 2 have results posted.

Phase 1 5Phase 2 4Phase 4 2No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Tau PET Outcomes With Anti-amyloid ImmunotherapiesEnrolling by invitationNCT06723015Phase 2
• A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's DiseaseRecruitingNCT06057909
• MR Elastography of Cognitive ImpairmentEnrolling by invitationNCT06029114
• MR Evaluation of Cerebrospinal Fluid (CSF) DynamicsRecruitingNCT04099823Not applicable
• Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's DiseaseRecruitingNCT03821857Phase 4
• Neuroimaging StudyEnrolling by invitationNCT03618186Phase 2
• Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal StudyRecruitingNCT02740634Not applicable
• Imaging of Brain Amyloid Plaques in the Aging PopulationEnrolling by invitationNCT00950430Phase 4
• Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot StudyCompletedNCT01834716Not applicableResults posted
• Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)CompletedNCT01607476Phase 2Results posted
• A Study of Caregiver Connections Via Technology in DementiaCompletedNCT05779839Not applicable
• A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of DementiaWithdrawnNCT05497817Not applicable
• Development of an EEG Diagnostic for Alzheimer's DiseaseCompletedNCT04954183
• ALSENLITE: Senolytics for Alzheimer's DiseaseActive, not recruitingNCT04785300Phase 1/2
• Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular BiomarkersCompletedNCT04567745Phase 1
• Compensatory Training to Support Brain Healthy Lifestyle Changes in Those at Risk for Alzheimer's DiseaseCompletedNCT04118985Not applicable
• 48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's DiseaseActive, not recruitingNCT04002583Not applicable
• Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)CompletedNCT03718494
• Behavioral Interventions to Prevent or Delay DementiaCompletedNCT02265757Not applicable
• The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length PolymorphismsCompletedNCT01780519Phase 1
• Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical ADCompletedNCT01723553Phase 1
• Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young AdultsCompletedNCT01609335Phase 1
• The Impact of Lorazepam on Cognition in APOE e4 CarriersCompletedNCT00586430Not applicable